Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma.

http://ift.tt/2ilMmVZ